Stem cell controversy could see new life with regent election shuffle

The departure of three University of Nebraska regents this year and the re-election campaign of a fourth is reviving debate over a controversial issue some believe should be laid to rest.

Two of the three departing regents, Chuck Hassebrook of Lyons and Jim McClurg of Lincoln, opposed a proposal considered by the Board of Regents in November 2009 that would have limited embryonic stem cell research at the University of Nebraska Medical Center to only cell lines approved under former President George W. Bush. Expansion had become a possibility since President Barack Obama relaxed the Bush guidelines.

Hassebrook and McClurg joined two other regents in killing the proposal by voting against the four who supported it. Pro-life activists believe embryonic stem cell research is morally wrong because harvesting the stem cells requires destroying an embryo.

Regent Randy Ferlic of Omaha, who supported the proposal to limit the research, also will leave the Board of Regents after this year. Bob Whitehouse of Papillion, who opposed the measure, is seeking re-election. Ten candidates are seeking the three retiring regents' seats, and candidate, Larry Bradley, is challenging Whitehouse.

Pro-life advocates said they see opportunity in the departure of two of the regents who opposed limiting stem cell research, but they aren't ready to say they'll ask like-minded regents to reintroduce a proposal to limit the research.

"That would be a place we could stand to gain if we had pro-lifers in the race who we're willing to endorse," said Julie Schmit-Albin, executive director of Nebraska Right to Life.

Nebraska Right to Life endorsed McClurg during his regents campaign, and Schmit-Albin said she believed he would have supported limiting embryonic stem cell research. When he voted against the proposal, however, Nebraska Right to Life ended its support of him, she said.

The group has become more careful in choosing candidates to endorse, Schmit-Albin said, sending out surveys to candidates and incumbents seeking re-election before the primary. It has yet to receive responses from those surveys, she said, so Nebraska Right to Life has yet to endorse any candidates this year.

Schmit-Albin said some regents candidates have contacted the group seeking endorsement, but she declined to name them. She said the group wouldn't endorse Whitehouse because he voted against the stem cell proposal in November 2009.

"He already has a record," she said.

Here is the original post:
Stem cell controversy could see new life with regent election shuffle

A new shortcut for stem cell programming

ScienceDaily (Mar. 22, 2012) Researchers at the University of Bonn artificially derive brain stem cells directly from the connective tissue of mice.

Scientists at the Life & Brain Research Center at the University of Bonn, Germany, have succeeded in directly generating brain stem cells from the connective tissue cells of mice. These stem cells can reproduce and be converted into various types of brain cells. To date, only reprogramming in brain cells that were already fully developed or which had only a limited ability to divide was possible. The new reprogramming method presented by the Bonn scientists and submitted for publication in July 2011 now enables derivation of brain stem cells that are still immature and able to undergo practically unlimited division to be extracted from conventional body cells. The results have now been published in the current edition of the journal Cell Stem Cell.

The Japanese stem cell researcher Professor Shinya Yamanaka and his team produced stem cells from the connective tissue cells of mice for the first time in 2006; these cells can differentiate into all types of body cells. These induced pluripotent stem cells (iPS cells) develop via reprogramming into a type of embryonic stage. This result made the scientific community sit up and take notice. If as many stem cells as desired can be produced from conventional body cells, this holds great potential for medical developments and drug research. "Now a team of scientists from the University of Bonn has proven a variant for this method in a mouse model," report Dr. Frank Edenhofer and his team at the Institute of Reconstructive Neurobiology (Director: Dr. Oliver Brstle) of the University of Bonn. Also involved were the epileptologists and the Institute of Human Genetics of the University of Bonn, led by Dr. Markus Nthen, who is also a member of the German Center for Neurodegenerative Diseases.

Edenhofer and his co-workers Marc Thier, Philipp Wrsdrfer and Yenal B. Lakes used connective tissue cells from mice as a starting material. Just as Yamanaka did, they initiated the conversion with a combination of four genes. "We however deliberately targeted the production of neural stem cells or brain stem cells, not pluripotent iPS multipurpose cells," says Edenhofer. These cells are known as somatic or adult stem cells, which can develop into the cells typical of the nervous system, neurons, oligodendrocytes and astrocytes.

The gene "Oct4" is the central control factor

The gene "Oct4" is a crucial control factor. "First, it prepares the connective tissue cell for reprogramming, later, however, Oct4 appears to prevent destabilized cells from becoming brain stem cells" reports the Bonn stem cell researcher. While this factor is switched on during reprogramming of iPS cells over a longer period of time, the Bonn researchers activate the factor with special techniques for only a few days. "If this molecular switch is toggled over a limited period of time, the brain stem cells, which we refer to as induced neural stem cells (iNS cells), can be reached directly," said Edenhofer. "Oct4 activates the process, destabilizes the cells and clears them for the direct reprogramming. However, we still need to analyze the exact mechanism of the cellular conversion."

The scientists at the University of Bonn have thus found a new way to reprogram cells, which is considerably faster and also safer in comparison to the iPS cells and embryonic stem cells. "Since we cut down on the reprogramming of the cells via the embryonic stage, our method is about two to three times faster than the method used to produce iPS cells," stresses Edenhofer. Thus the work involved and the costs are also much lower. In addition, the novel Bonn method is associated with a dramatically lower risk of tumors. As compared to other approaches, the Bonn scientists' method stands out due to the production of neural cells that can be multiplied to a nearly unlimited degree.

Low risk of tumor and unlimited self renewal

A low risk of tumor formation is important because in the distant future, neural cells will replace defective cells of the nervous system. A vision of the various international scientific teams is to eventually create adult stem cells for example from skin or hair root cells, differentiate these further for therapeutic purposes, and then implant them in damaged areas. "But that is still a long way off," says Edenhofer. However, the scientists have a rather urgent need today for a simple way to obtain brain stem cells from the patient to use them to study various neurodegenerative diseases and test drugs in a Petri dish. "Our work could form the basis for providing practically unlimited quantities of the patient's own cells." The current study was initially conducted on mice. "We are now extremely eager to see whether these results can also be applied to humans," says the Bonn scientist.

Share this story on Facebook, Twitter, and Google:

Read more:
A new shortcut for stem cell programming

Stem Cell Transplant Program Offered at UVA Medical Center

What used to be medical trash is now treating cancer. The University of Virginia's Medical Center is the first place in Virginia to take advantage of stem cells from umbilical cords and they are pleased with the results.

Dr. Mary Laughlin, the director of stem cell transplantation at UVA,said, "These are cells that are routinely thrown away, these cells save lives."

A lab within the UVA Medical Center contains numerous tubes where non-embryonic stem cells reside. They come from umbilical cord blood and give hope topatients suffering leukemia, multiple myeloma and lymphoma.

Dr. Laughlin added, "They can completely replace a patient's bone marrow in the immune system. Oneof 10 cancer patients are able to find those cells through existing adult registries."

Thefive million babies that are born each year will soon solve that problem. The cells that are normally tossed out attack cancer cells.

Denise Mariconda, a nurse within the stem cell transplant program, stated, "It looks like a blood transfusion." Dr. Laughlin added, "It is in many ways like a cancer vaccine."

The first transplants were made in January and the transplant program at the UVA Medical Center admits it takes getting used to.

Mariconda said, "It is a process that's not like having your heart fixed in a one-day setting and you know that it's better."

These cells are not cause for controversy. Dr. Laughlin said, "Use of cord-blood is approved by all religious groups including the Vatican."

Babies' immune systems are not fully educated at the time of birth, making these cells effective. Dr. Laughlin, added, "That allows us to cross transplant barriers."

Read the original post:
Stem Cell Transplant Program Offered at UVA Medical Center

Researchers: Stem cell cures are on the way

SACRAMENTO, Calif. (KGO) -- Stem cells are the focus of debate in Sacramento where an effort is underway to use more than $1 billion in voter-approved bonds to continue experiments that may one day cure disease.

Major medical breakthroughs take time, but as public money for stem cell research is spent down, the pressure to cure something is going up.

The California Institute for Regenerative Medicine (CIRM) is about to enter a crucial stage in stem cell research, going to clinical trials. The most promising experiments could cure diabetes, HIV, sickle cell anemia, and blindness in the elderly. "You don't really get to find out whether the potential of the treatment is really going to be effective until you start to treat the patients," Alan Trounson explained.

CIRM's board is discussing how much to allocate for that trial phase. Through the 2004 voter-approved bonds under Proposition 71, it has already given out or spent half of the $3 billion, but despite the medical promise, there's little to show for it beyond basic research and several high-tech labs. Still, the agency says the breakthroughs will come over the next few years, way ahead of the rest of the world. "This would all be happening in California, all driven by this Proposition 71 money," Trounson said.

The bond money is expected to last only several more years. One option is to ask voters to approve more bonds, something taxpayer groups oppose. "When people think about bond financing, they think about a bridge, a school, a canal. But, stem cell research is just kind of out there," said Jon Coupal with the Howard Jarvis Taxpayers Association.

Rancher Diana Souza says it would be a shame to stop public funding of stem cell research. Through clinical trials at UC Davis Medical Center not financed by Prop 71 money, she says stem cells helped restore full use of her severely fractured arm. "I hope they can continue doing this because it is a miracle. It does work. And, I have a good arm to prove it," she said.

CIRM's transition plan, already submitted to Gov. Brown and lawmakers, assumes no more taxpayer support after the bond money runs out. The agency is also thinking about becoming a non-profit and letting others carry on the work.

(Copyright 2012 KGO-TV/DT. All Rights Reserved.)

Get more Politics

Tags:

Original post:
Researchers: Stem cell cures are on the way

Dr. Nikolai Tankovich, President Of Stemedica, Appointed Legate to The Center of Science and Society at The University …

The Board of Trusties of the Centre for Science and Society at Trinity College of the University of Oxford, England has appointed Nikolai Tankovich, MD, PhD, FASLMS as a Legate of the Centre. Dr. Tankovich is President and Chief Medical officer of Stemedica Cell Technologies, Inc. and Chairman of Stemedica International S.A. a manufacturer of ischemic tolerant adult allogeneic stem cells.

(PRWEB) March 15, 2012

Dr. Tankovich has been a frequent lecturer and guest speaker at the Centre for the last several years. The position of Legate recognizes the importance of his continuing role in reporting on the latest worldwide trends in regenerative medicine and biotechnology. Dr Tankovich is a surgical oncologist who holds a Masters Degree in Physics and a PhD in Biophysics. He is a Fellow of the American Society of Laser Medicine and Surgery. Dr. Tankovich is the author of multiple patents in the fields of stem cells and laser science.

Dr. Frank C. Schuller, Director of the Centre for Science and Society at Trinity College said, We are pleased to formalize our valued relationship with Dr. Tankovich by naming him a Legate of the Center. This honor is in recognition of his extensive contributions to advancing scientific understanding at the University of Oxford, and in anticipation of many years of continuing involvement.

Speaking of his lecturing at Trinity College, Dr. Tankovich noted, It is always a pleasure to present the latest medical and scientific information to some of the brightest researchers and scientists in the world. I look forward to working with The Center to explore the boundaries of science and technology to help translate research into meaningful cures for many of the presently chronic diseases and conditions that are prevalent today.

Richard Silcock, Associate Director of the Centre, said, "During recent years, Dr. Tankovich has generously contributed his extensive knowledge and practical expertise to stimulate lively debates at the Centre on stem cell research and its medical or commercial applications. He joins a panel of Legates who have distinguished themselves in their careers. We are honored that Dr. Tankovich will be an ambassador for the Centre to promote discussion of important issues connecting science and society."

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies Inc. (http://www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The Company is currently conducting clinical trials for stroke under US IND using ischemic tolerant mesenchymal (itMSC) stem cells. Regulatory pathways for spinal cord injury, diabetic retinopathy, acute myocardial infarct, acute respiratory distress syndrome and wound repair are also underway.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan(at)stemedica(dot)com.

Dave McGuigan Stemedica Cell Technologies Inc (858) 658-0910 Email Information

Read the original here:
Dr. Nikolai Tankovich, President Of Stemedica, Appointed Legate to The Center of Science and Society at The University ...

Gut Cells Turned To Insulin Factories – New Type l Diabetes Treatment

Editor's Choice Academic Journal Main Category: Diabetes Article Date: 13 Mar 2012 - 12:00 PDT

email to a friend printer friendly opinions

Current Article Ratings:

The study was carried out by Chutima Talchai, Ph.D, a New York Stem Cell Foundation-Druckenmiller Fellow, and Domenico Accili, M.D., professor of medicine at Columbia University Medical Center.

Type 1 diabetes is an autoimmune disease that kills cells in the pancreas which produce insulin, resulting in high levels of glucose in the blood. As the pancreas is unable to replace these cells, individuals suffering with the disease must inject insulin into themselves in order to manage their blood sugar. Patients must also monitor their sugar levels numerous times a day, as blood glucose that is too low or too high can be fatal.

For scientists researching type 1 diabetes, one of the leading goals is to replace lost insulin-producing cells with new cells that release insulin into the bloodstream as needed. Even though researchers are able to generate these cells in the laboratory from embryonic stem cells, they are not suitable for transplant in patients as they do not release insulin appropriately in response to sugar levels, potentially resulting in a deadly condition called hypoglycemia.

In the intestine of mice, the researchers found that certain gastrointestinal progenitor cells are able to generate insulin-producing cells.

Usually, progenitor cells are responsible for generating a vast range of cells, such as gastric inhibitory peptide, cells that produce serotonin, as well as other hormones secreted into the GI tract and bloodstream.

The researchers discovered that when they switched off Foxo1 (a gene known to contribute in cell fate decisions), the progenitor cells also generated cells that produced insulin. In addition, the team found that although more cells were produced when Foxo1 was switched off early in development, they were also produced when the Foxo1 was switched off in adult mice.

Dr. Accili, explained:

Originally posted here:
Gut Cells Turned To Insulin Factories - New Type l Diabetes Treatment

Biostem U.S., Corp. Appoints Thomas Prendergast to SAMBA

More Topics: Choose a Sector Accounting Firms Advertising/Media/Communications Capital CEO/Board General Business Health/Biotech Internet/Technology Investment Firms Law Firms Mergers & Acquisitions Money Managers People Private Companies Public Companies Venture Capital

Posted March 12, 2012

Thomas W. Prendergast

Cardiothoracic Surgeon Specializes in Heart Transplantation

CLEARWATER, FL -- Biostem U.S., Corporation (OTCQB: BOSM) (PINKSHEETS: BOSM) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of cardiothoracic surgeon Thomas W. Prendergast, M.D. to its Scientific and Medical Board of Advisors (SAMBA).

Biostem CEO, Dwight Brunoehler stated, "The Company is now positioned for growth and international expansion. Adding a world class team of clinical, laboratory, and regulatory experts for our Scientific and Medical Board of Advisors to guide our pursuits is essential. Dr. Prendergast brings a wealth of experience not only in the scientific aspects of stem cell use in regenerative medicine, but also in forging research and international economic development opportunities."

Dr. Prendergast is a busy clinical cardiothoracic surgeon, who performs 200-250 open-heart operations and 5 to 15 heart transplants each year. He is deeply involved in numerous clinical and research activities associated with stem cells and heart repair. He is presently Director of Cardiac Transplantation at Robert Wood Johnson University Hospital in New Brunswick, New Jersey where he holds an Associate Professorship of Surgery at the University of Medicine and Dentistry of New Jersey. In addition to being an active participant in stem cell research program development and teaching medical students and residents, his other interests include medical research funding and humanitarian development of programs for Disabled American Veterans.

Dr. Prendergast received his undergraduate degrees in biophysics and Psychology, as well as his medical degree, at Pennsylvania State University. His general surgery residency was for five years at the University of Massachusetts Medical School. His cardiothoracic surgery training was at the University of Southern California School of Medicine, including the Los Angeles County Medical Center. Subsequent fellowship training included pediatric cardiac surgery at Children's Hospital of LA, along with thoracic transplant fellowships at University of Southern California in Los Angeles and at Temple University Hospital in Philadelphia. He spent three years at the University of Kansas establishing thoracic transplant programs until returning to Temple University Hospital as one of their staff heart and lung transplant surgeons. Subsequent to his time at Temple, he joined up with Newark Beth Israel/St. Barnabas Hospitals, where he assumed directorship as the Chief of Cardiac Transpla ntation and Mechanical Assistance.

Regarding his appointment to the Biostem U.S. Scientific and Medical Board of Advisors, Dr. Prendergast said, "I am looking forward with excitement to working again with Dwight at Biostem. The expansion plan is sound, well paced, and will afford improved quality of life opportunities to many people around the world."

About Biostem U.S., Corporation

Read more:
Biostem U.S., Corp. Appoints Thomas Prendergast to SAMBA

BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis

NEW YORK & PETACH TIKVAH, ISRAEL--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a developer of adult stem cell technologies and CNS therapeutics, announces plans to initiate a preclinical study assessing the efficacy of its NurOwn stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and the Company is working to advance MS into preclinical development in Q2 2012.

Based on initial promising pre-clinical data published by the Company's Chief Scientist, Prof. Daniel Offen of Tel Aviv University, BrainStorm has decided to explore MS as an additional indication for its NurOwn technology. The Company will draw plans to initiate pre-clinical safety trials, after which it will seek a leading medical center specializing in MS for clinical trials.

We have been focused on growing our pipeline of indications using our NurOwn stem-cell technology, commented Dr. Adrian Harel, Acting CEO of BrainStorm Cell Therapeutics. As we continue our ongoing trials to evaluate the safety, tolerability and therapeutic effects of NurOwn in ALS patients, we have determined through positive preliminary animal data that MS will be the next indication to pursue using our technology.

About NurOwn BrainStorms core technology, NurOwn, is based on the scientific achievements of Professor Eldad Melamed, former Head of Neurology, Rabin Medical Center, and Tel-Aviv University, and Professor Daniel Offen, Head of the Neuroscience Laboratory, Felsenstein Medical Research Center at the Tel-Aviv University.

The NurOwn technology processes adult human mesenchymal stem cells that are present in bone marrow and are capable of self-renewal as well as differentiation into many cell types. The research team is among the first to have successfully achieved the in-vitro differentiation of adult bone marrow cells (animal and human) into cells capable of releasing neurotrophic factors, such as glial-derived neurotrophic factor (GDNF), by means of a specific differentiation-inducing culture medium.

About Multiple Sclerosis (MS) Multiple sclerosis (MS) is believed to be an autoimmune disorder that affects the central nervous system (CNS). Autoimmune means that the bodys immune system mistakenly attacks its own tissue, in this case, the tissues of the CNS. With MS, autoimmune damage to neurons disrupts the bodys ability to send and receive signals, thus causing MS-related symptoms. Symptoms may vary due to the location and extent of the damage. Worldwide, MS may affect more than 2 million individuals, including approximately 400,000 people in the United States.

About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel-Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

The rest is here:
BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis

UCLA scientists find insulin, nutrition prevent blood stem cell differentiation in fruit flies

Public release date: 11-Mar-2012 [ | E-mail | Share ]

Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Health Sciences

UCLA stem cell researchers have shown that insulin and nutrition keep blood stem cells from differentiating into mature blood cells in Drosophila, the common fruit fly, a finding that has implications for studying inflammatory response and blood development in response to dietary changes in humans.

Keeping blood stem cells, or progenitor cells, from differentiating into blood cells is important as they are needed to create the blood supply for the adult fruit fly.

The study found that the blood stem cells are receiving systemic signals from insulin and nutritional factors, in this case essential amino acids, that helped them to maintain their "stemness," said study senior author Utpal Banerjee, professor and chairman of the molecular, cell and developmental biology department in Life Sciences and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine at UCLA.

"We expect that this study will promote further investigation of possible direct signal sensing mechanisms by mammalian blood stem cells," Banerjee said. "Such studies will probably yield insights into chronic inflammation and the myeloid cell accumulation seen in patients with type II diabetes and other metabolic disorders."

The study appears March 11, 2012 in the peer-reviewed journal Nature Cell Biology.

In the flies, the insulin signaling came from the brain, which is an organ similar to the human pancreas, which produces insulin. That insulin was taken up by the blood stem cells, as were amino acids found in the fly flood, said Ji Won Shim, a postdoctoral fellow in Banerjee's lab and first author of the study.

Shim studied the flies while in the larval stage of development. To see what would happen to the blood stem cells, Shim placed the larvae into a jar with no food - they usually eat yeast or cornmeal and left them for 24 hours. Afterward, she checked for the presence of blood stem cells using specific chemical markers that made them visible under a confocal microscope.

"Once the flies were starved and not receiving the insulin and nutritional signaling, all the blood stem cells were gone," Shim said. "All that were left were differentiated mature blood cells. This type of mechanism has not been identified in mammals or humans, and it will be intriguing to see if there are similar mechanisms at work there."

More here:
UCLA scientists find insulin, nutrition prevent blood stem cell differentiation in fruit flies

Insulin, nutrition prevent blood stem cell differentiation

LOS ANGELES UCLA stem cell researchers have shown that insulin and nutrition prevent blood stem cells from differentiating into mature blood cells in Drosophila, the common fruit fly, a finding that has implications for studying inflammatory response and blood development in response to dietary changes in humans.

Keeping blood stem cells, or progenitor cells, from differentiating into blood cells is important as blood stem cells are needed to create the blood supply for the adult fruit fly.

The study found that the blood stem cells are receiving systemic signals from insulin and nutritional factors, in this case essential amino acids, that helped them to maintain their "stemness," said study senior author Utpal Banerjee, the Irving and Jean Stone Professor and chairman of molecular, cell and developmental biology in the UCLA Division of Life Sciences and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine at UCLA.

"We expect that this study will promote further investigation of possible direct signal sensing mechanisms by mammalian blood stem cells," Banerjee said. "Such studies will probably yield insights into chronic inflammation and the myeloid cell accumulation seen in patients with type II diabetes and other metabolic disorders."

The study appeared Sunday (March 11) in the peer-reviewed journal Nature Cell Biology.

In the flies, the insulin signaling came from the brain, which is an organ similar to the human pancreas, which produces insulin. That insulin was taken up by the blood stem cells, as were amino acids found in the fly blood, said Ji Won Shim, a postdoctoral fellow in Banerjee's lab and first author of the study.

Shim studied the flies while in the larval stage of development. To see what would happen to the blood stem cells, Shim placed the larvae into a jar with no food they usually eat yeast or cornmeal and left them for 24 hours. Afterward, she checked for the presence of blood stem cells using specific chemical markers that made them visible under a confocal microscope.

"Once the flies were starved and not receiving the insulin and nutritional signaling, all the blood stem cells were gone," Shim said. "All that were left were differentiated mature blood cells. This type of mechanism has not been identified in mammals or humans, and it will be intriguing to see if there are similar mechanisms at work there."

In the fruit fly, the only mature blood cells present are myeloid cells, Shim said. Diabetic patients have many activated myeloid cells that could be causing disease symptoms. It may be that abnormal activation of myeloid cells and abnormal metabolism play a major role in diabetes.

"Metabolic regulation and immune response are highly integrated in order to function properly dependent on each other. Type II diabetes and obesity, both metabolic diseases, are closely associated with chronic inflammation, which is induced by abnormal activation of blood cells," Shim said. "However, no systemic study on a connection between blood stem cells and metabolic alterations had been done. Our study highlights the potential linkage between myeloid-lineage blood stem cells and metabolic disruptions."

Originally posted here:
Insulin, nutrition prevent blood stem cell differentiation